Search for “FDA approved shockwave therapy” and you will find contradictory information. Some clinic websites claim their devices are “FDA approved.” Others market shockwave therapy as an “innovative” treatment still seeking approval. Neither description is quite right, and the confusion matters because it affects how patients, insurers, and providers evaluate the treatment.
The regulatory status of extracorporeal shockwave therapy (ESWT) is more nuanced than a simple yes or no – and understanding it helps you make a better-informed decision about your care.
FDA Clearance vs. FDA Approval: The Distinction That Matters
First, the terminology. Medical devices and pharmaceutical drugs go through different regulatory pathways, and mixing up the terms creates confusion.
FDA approval is the process for new drugs. It involves multi-phase clinical trials, often spanning years and costing hundreds of millions of dollars. When people say a drug is “FDA approved,” this is what they mean.
FDA clearance is the process for most medical devices. It uses the 510(k) pathway, which requires the manufacturer to demonstrate that their device is “substantially equivalent” to an already-marketed device (a predicate device). This is a less rigorous process than drug approval but still requires evidence of safety and effectiveness.
Shockwave therapy devices are medical devices. They go through 510(k) clearance, not drug approval. So technically, no shockwave therapy device is “FDA approved” – but several are “FDA-cleared,” which is the correct regulatory term for devices.
When a clinic says their shockwave therapy is “FDA approved,” they are using imprecise language. The correct statement is “FDA-cleared.”
Which Indications Are Currently FDA-Cleared?
The FDA has cleared shockwave therapy devices for a limited number of specific indications:
Chronic proximal plantar fasciitis (heel pain). The OssaTron device received 510(k) clearance in 2000 for treating chronic proximal plantar fasciitis in patients who have not responded to conservative treatment for at least 6 months. Several other devices have since received clearance for this indication. This is the most established FDA-cleared use of ESWT in the United States.
Lateral epicondylitis (tennis elbow). Select devices have received 510(k) clearance for chronic lateral epicondylitis. The clinical trials supporting this clearance demonstrated meaningful pain reduction compared to sham treatment.
Diabetic foot ulcers. Some ESWT devices have received clearance for promoting wound healing in diabetic foot ulcers, though this is a newer and less widely discussed clearance.
These cleared indications represent a fraction of the conditions for which ESWT is used clinically. The gap between what is cleared and what is practiced is significant – and intentional.
The Off-Label Landscape
The majority of shockwave therapy treatments administered in the United States are for off-label indications. This includes ESWT for:
- Achilles tendinopathy
- Patellar tendinopathy
- Calcific shoulder tendinitis
- Hip bursitis / greater trochanteric pain syndrome
- Shin splints (medial tibial stress syndrome)
- Myofascial trigger points
- Erectile dysfunction
- Cellulite reduction
“Off-label” does not mean illegal, experimental, or unsupported by evidence. It means the device manufacturer has not pursued or obtained FDA clearance for that specific use. Once a device receives 510(k) clearance for any indication, providers can legally use it for other conditions based on their clinical judgment.
Off-label use is a normal part of medicine. An estimated 20% of all prescriptions in the United States are for off-label uses. The practice is particularly common with medical devices, where the cost of seeking clearance for each new indication creates a financial barrier that does not reflect the clinical evidence.
Why More Indications Are Not Cleared
If clinical trials support ESWT for conditions like calcific tendinitis and Achilles tendinopathy, why have not manufacturers sought clearance for these uses? The answer is primarily economic:
Cost. Conducting the clinical trials required for a 510(k) submission costs millions of dollars. Manufacturers must weigh this investment against the expected return.
Existing market access. Because off-label use is legal, manufacturers can already sell their devices to providers who use them for non-cleared indications. The commercial incentive to pursue additional clearances is limited.
Market size. Some conditions treated with ESWT affect relatively small patient populations. The cost of clearance may not be justified by the market opportunity.
International evidence. ESWT is widely used and endorsed by professional medical societies in Europe, Asia, and elsewhere. Manufacturers may focus their regulatory efforts on markets where clearance is more directly tied to reimbursement.
The result is a disconnect: conditions with robust clinical evidence (calcific shoulder tendinitis, for example, has some of the strongest ESWT data of any indication) may lack FDA clearance, while the cleared indications are not necessarily the ones with the strongest evidence.
The ED Device Gray Area
The shockwave therapy for erectile dysfunction market deserves special mention because of its unique regulatory landscape.
Low-intensity shockwave therapy (Li-SWT) for ED has a growing evidence base, with multiple RCTs and meta-analyses. However, many devices marketed for ED treatment in the United States are positioned as “wellness devices” rather than medical devices, which allows them to sidestep FDA oversight entirely.
This creates a confusing marketplace:
- Some legitimate ESWT devices cleared for musculoskeletal use are used off-label for ED by licensed medical providers
- Some “acoustic wave therapy” devices marketed directly for ED have not gone through the 510(k) process at all
- Consumer-facing marketing sometimes blurs the line between FDA-cleared medical devices and unregulated wellness products
For patients considering shockwave therapy for ED, the key question is whether the provider is using a legitimate medical device with proper clinical protocols – not whether the device has specific FDA clearance for ED. Learn more on our shockwave therapy for ED condition page.
What This Means for Insurance Coverage
FDA clearance status directly affects insurance reimbursement. Generally:
- FDA-cleared indications (plantar fasciitis, tennis elbow): insurance coverage is possible but inconsistent. Many plans still consider ESWT experimental or investigational even for cleared indications.
- Off-label indications: insurance coverage is unlikely. Most patients pay out of pocket.
This is one of the practical consequences of the limited clearance landscape. Even when clinical evidence supports ESWT for a condition, the lack of formal FDA clearance gives insurers a reason to deny coverage. Read more about shockwave therapy costs and insurance to understand pricing for your specific situation.
The Bottom Line
Shockwave therapy is FDA-cleared (not “approved”) for chronic plantar fasciitis and lateral epicondylitis through the 510(k) medical device pathway. Most other clinical uses – including several with strong research support – are considered off-label. Off-label use is legal, common, and often supported by clinical evidence, but it does affect insurance coverage.
When evaluating shockwave therapy, focus on the clinical evidence for your specific condition rather than on FDA status alone. A treatment can be well-supported by research and used routinely in clinical practice without having specific regulatory clearance for every indication.
Explore our complete guide to conditions treated with shockwave therapy to learn more about evidence-based ESWT applications.
References
- U.S. Food and Drug Administration. 510(k) Premarket Notification Database. OssaTron device clearance for plantar fasciitis. 2000. Available at: https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm
Medical Disclaimer: This content is for informational purposes only and does not constitute medical advice. Shockwave therapy outcomes vary by individual and condition. Consult a qualified healthcare provider to determine if shockwave therapy is appropriate for your situation.